Profile data is unavailable for this security.
About the company
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
- Revenue in SEK (TTM)0.00
- Net income in SEK-30.87m
- Incorporated2015
- Employees9.00
- LocationAmniotics AB (publ)Medicon Village, Scheelevagen 2LUND 223 63SwedenSWE
- Websitehttps://www.amniotics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagonal Bio AB | 23.00k | -11.62m | 5.17m | 4.00 | -- | 0.1833 | -- | 224.70 | -0.1407 | -0.1407 | 0.0002 | 0.0704 | 0.0008 | -- | 2.00 | 4,600.00 | -38.99 | -- | -43.85 | -- | -32,443.48 | -- | -50,504.35 | -- | 1.72 | -15.50 | 0.00 | -- | -88.67 | -- | 27.75 | -- | -- | -- |
2cureX AB | 87.00k | -26.35m | 9.68m | 14.00 | -- | 3.48 | -- | 111.28 | -1.50 | -1.50 | 0.0049 | 0.1582 | 0.0047 | -- | 0.0295 | 6,214.29 | -143.13 | -38.93 | -174.78 | -44.42 | -10,942.53 | -22,717.96 | -30,282.76 | -39,378.78 | -- | -13.61 | 0.00 | -- | 72.22 | -- | -9.23 | -- | -57.30 | -- |
Gabather AB | 0.00 | -10.68m | 13.47m | -- | -- | -- | -- | -- | -0.6373 | -0.6373 | 0.00 | -0.1818 | 0.00 | -- | -- | -- | -192.36 | -56.57 | -- | -67.36 | -- | -- | -- | -17,298,800.00 | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- |
Amniotics AB (publ) | 0.00 | -30.87m | 13.67m | 9.00 | -- | 0.8722 | -- | -- | -0.0374 | -0.0374 | 0.00 | 0.0057 | 0.00 | -- | -- | 0.00 | -112.25 | -101.09 | -362.62 | -149.91 | -- | -- | -- | -- | 1.12 | -16.17 | 0.00 | -- | -- | -- | 35.75 | -- | -- | -- |
Lidds AB | 0.00 | -25.60m | 18.97m | 1.00 | -- | 2.46 | -- | -- | -0.4664 | -0.4664 | 0.00 | 0.0566 | 0.00 | -- | -- | 0.00 | -97.07 | -46.33 | -111.99 | -51.61 | -- | -1,934.24 | -- | -3,076.68 | -- | -- | 0.1044 | -- | -100.00 | -- | -9.08 | -- | -- | -- |
Circio Holding ASA | 119.40k | 9.23m | 19.47m | 8.00 | 1.20 | -- | 1.95 | 163.07 | 0.6836 | 0.6836 | 0.0156 | -4.05 | 0.0043 | -- | 0.0145 | 11,181.82 | 33.11 | -46.58 | -- | -53.40 | -- | -- | 7,730.08 | -6,902.00 | -- | -- | -- | -- | -98.77 | 35.43 | 74.42 | -- | -- | -- |
Stayble Therapeutics AB | 0.00 | -20.40m | 28.64m | 2.00 | -- | 2.34 | -- | -- | -0.6413 | -0.6413 | 0.00 | 0.2795 | 0.00 | -- | -- | 0.00 | -81.91 | -78.64 | -93.24 | -95.58 | -- | -- | -- | -- | -- | -- | 0.065 | -- | -- | -- | 3.22 | -- | -- | -- |
SoftOx Solutions AS | 1.61m | -58.81m | 33.34m | 7.00 | -- | 0.2297 | -- | 20.69 | -0.7729 | -0.7729 | 0.0022 | 0.0766 | 0.0166 | -- | 0.493 | 237,141.40 | -60.65 | -50.11 | -81.43 | -63.61 | -- | -- | -3,649.40 | -639.34 | 0.4049 | -2.76 | 0.1463 | -- | -1.88 | 10.06 | 44.55 | -- | 39.43 | -- |
Scandion Oncology A/S | 0.00 | -54.53m | 33.86m | 4.00 | -- | 0.725 | -- | -- | -0.3727 | -0.3727 | 0.00 | 0.2014 | 0.00 | -- | -- | 0.00 | -72.35 | -- | -84.88 | -- | -- | -- | -- | -- | -- | -- | 0.0058 | -- | -- | -- | 48.89 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
FCG Fonder ABas of 30 Aug 2024 | 283.66k | 0.01% |